STILNOX TABLET 10 mg Singapore - English - HSA (Health Sciences Authority)

stilnox tablet 10 mg

sanofi-aventis singapore pte. ltd. - zolpidem tartrate - tablet, film coated - 10 mg - zolpidem tartrate 10 mg

CORDARONE INJECTION 150 mg3 ml Singapore - English - HSA (Health Sciences Authority)

cordarone injection 150 mg3 ml

sanofi-aventis singapore pte. ltd. - amiodarone hcl - injection - 150 mg/3 ml - amiodarone hcl 150 mg/3 ml

PRALUENT SOLUTION FOR INJECTION PRE-FILLED SYRINGE 150 MGML Singapore - English - HSA (Health Sciences Authority)

praluent solution for injection pre-filled syringe 150 mgml

sanofi-aventis singapore pte. ltd. - alirocumab - injection, solution - alirocumab 150mg

PRALUENT SOLUTION FOR INJECTION PRE-FILLED SYRINGE 75MGML Singapore - English - HSA (Health Sciences Authority)

praluent solution for injection pre-filled syringe 75mgml

sanofi-aventis singapore pte. ltd. - alirocumab - injection, solution - alirocumab 75mg

PLAVIX 75 MG Israel - English - Ministry of Health

plavix 75 mg

sanofi israel ltd - clopidogrel as hydrogen sulfate - film coated tablets - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - secondary prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.